STOCKHOLM--(BUSINESS WIRE)--Regulatory News: BioGaia (STO:BIOGB) has signed an exclusive distributor agreement with Phillips Pharma Group for the rights to sell BioGaia ProTectis drops, tablets and ...
BioGaia's probiotics have received top ratings and the company has seen rapid growth, but concerns are raised about the company's ability to maintain this amidst leadership changes. The company ...
A study published in the Journal of Pediatrics found L. reuteri Protectis, a probiotic of BioGaia, reduced both frequency and severity of abdominal pain in children, compared to a placebo. Zvi Weizman ...
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, ...
One of the beneficial gut bacteria residing in the human gut, which normally cannot survive in an environment with oxygen, can now be made oxygen-tolerant. This is a key finding in the development of ...
* A randomized, double-blind, placebo-controlled study in 93 children diagnosed with functional abdominal pain showed that L. reuteri Protectis reduced both frequency and severity of pain compared to ...
* RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN HEALTHY SAILORS SHOWED THAT SUPPLEMENTATION OF L. REUTERI PRODENTIS SIGNIFICANTLY REDUCED BLEEDING OF GUMS COMPARED TO PLACEBO * RESULT OF THIS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results